responses to olutasidenib in patients with aml who have failed treatment with venetoclax
Published 6 days ago • 34 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
1:08
the importance of predicting venetoclax response in patients with aml
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:04
using mrd to identify which patients with aml will benefit the most from transplantation
-
7:50
which aml patients benefit most from venetoclax treatment?
-
3:33
venetoclax (bcl 2 inhibitor)
-
43:10
venetoclax plus gilteritinib for flt3-mutated relapsed/refractory acute myeloid leukemia
-
2:19
cladribine ldac venetoclax alternated with azacitidine venetoclax in older patients with aml
-
0:59
treatment options for elderly cll patients or those with comorbidities beyond bcl2 inhibitors
-
1:17
evaluating response to treatment in patients with emd
-
2:37
maintenance venetoclax and 5-azacytidine in patients with aml
-
5:36
venetoclax and azacitidine in mds patients
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:27
quizartinib, venetoclax, and decitabine in patients with flt3-itd aml: a phase i/ii trial
-
1:33
the use of gilteritinib in post-transplant maintenance for aml with flt3-itd
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml